Florida Health Daily
SEE OTHER BRANDS

Your best source on healthcare and wellness news from Florida

Florida Health Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.

Press releases published on September 24, 2025

PureCipher Open Sources SecureMCP - Redefining Trust for the Era of Agentic AI
Adze Biotechnology and King’s College London Announce Clinical Collaboration in hard-to-treat Breast Cancers
Pre-Orders Open for Scale Up Blueprint™ by Maja Kazazic
NOTICE TO CUSTOMERS OF BROKER RODGER THOMAS AND NEWBRIDGE SECURITIES WHO PURCHASED GWG AND ALTERNATIVE INVESTMENTS
Debut with Purpose-Driven Approach for Clinical Solutions: Minerva Joins Global Site Solutions Summit 2025
Publix and Leading Brands Unite in Upcoming Extra Savings Flyer to Donate to Florida Breast Cancer Charities
Digital Auxilius Joins SCRS 2025 as a Premier Plus Sponsor Supporting Site Connectivity
Syncora Joins SCRS 2025 to Address Study Startup Bottlenecks
Range Impact Announces $550,000 Capital Raise
Verano to Report Third Quarter 2025 Financial Results on October 29, 2025
SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury
Precision Optics Schedules Fourth Quarter and Fiscal Year 2025 Conference Call for September 29, 2025
uniQure Announces $200 Million Proposed Public Offering
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
Shareholders of Verona Pharma Approve Proposed Acquisition by Merck
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
Inventiva to Host Analyst and Investor Event on October 8, 2025

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions